Pfizer and BioNTech Win Bid to Invalidate CureVac’s UK COVID Vaccine Patents

LONDON – On Tuesday, Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) won their attempt to invalidate two of rival CureVac’s (NASDAQ: CVAC) patents at London’s High Court.

Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech’s COVID-19 vaccine.

Tuesday’s ruling relates to the London leg of Pfizer, BioNTech, and CureVac’s global legal battle, which also involves litigation in the United States and Germany.

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are separately involved in a case with Moderna over their rival COVID-19 vaccines.

The High Court ruled in that case in July that one of Moderna’s mRNA patents was valid and Pfizer and BioNTech’s Comirnaty vaccine had infringed it. Pfizer and BioNTech have been granted permission to appeal against that decision.

(Source: ReutersReuters)

BioNTech CureVac NASDAQ: BNTX NASDAQ: CVAC NYSE: PFE Pfizer

Jennifer Tacker

Jennifer Tacker is a staff writer at ABBO News. She holds a B.A. from the University of Waterloo and a B.Ed from Western University. Jennifer has been active in the stock market and crypto sector for a decade. She specializes in technical analysis and trading strategies.

See Full Bio